Paper41892478
Bacteriophage Therapy Against Shigella spp.: A Precision Antimicrobial Strategy.
Scarlata GGM and 5 others. Antibiotics (Basel), 2026. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Bacteriophage Therapy Against Shigella spp.: A Precision Antimicrobial Strategy. Papers, record 41892478. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41892478
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References100
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32,652,061 | Metagenome Data on Intestinal Phage-Bacteria Associations Aids the Development of Phage Therapy against Pathobionts. | Cell Host Microbe | 2020 | https://conductscience.org/library/papers/32652061 | PubMed |
| 2 | 32,094,257 | Fitness Trade-Offs Resulting from Bacteriophage Resistance Potentiate Synergistic Antibacterial Strategies. | Infect Immun | 2020 | https://conductscience.org/library/papers/32094257 | PubMed |
| 3 | 35,080,902 | A Novel Method to Create Efficient Phage Cocktails via Use of Phage-Resistant Bacteria. | Appl Environ Microbiol | 2022 | https://conductscience.org/library/papers/35080902 | PubMed |
| 4 | 39,711,781 | Synergistic efficacy of phage Henu10 with antibiotics against Shigella dysenteriae with insight into phage resistance and fitness trade-offs. | Front Cell Infect Microbiol | 2024 | https://conductscience.org/library/papers/39711781 | PubMed |
| 5 | 26,909,243 | Bacteriophage administration significantly reduces Shigella colonization and shedding by Shigella-challenged mice without deleterious side effects and distortions in the gut microbiota. | Bacteriophage | 2015 | https://conductscience.org/library/papers/26909243 | PubMed |
| 6 | 20,228,623 | A new paradigm of bacteria-gut interplay brought through the study of Shigella. | Proc Jpn Acad Ser B Phys Biol Sci | 2010 | https://conductscience.org/library/papers/20228623 | PubMed |
| 7 | 31,487,893 | Bacteriophages as Alternatives to Antibiotics in Clinical Care. | Antibiotics (Basel) | 2019 | https://conductscience.org/library/papers/31487893 | PubMed |
| 8 | 40,790,209 | Recent insights on challenges encountered with phage therapy against gastrointestinal-associated infections. | Gut Pathog | 2025 | https://conductscience.org/library/papers/40790209 | PubMed |
| 9 | 34,801,778 | European regulatory aspects of phage therapy: magistral phage preparations. | Curr Opin Virol | 2022 | https://conductscience.org/library/papers/34801778 | PubMed |
| 10 | 39,804,673 | PHIStruct: improving phage-host interaction prediction at low sequence similarity settings using structure-aware protein embeddings. | Bioinformatics | 2024 | https://conductscience.org/library/papers/39804673 | PubMed |
| 11 | 38,604,200 | Fine-tuning the gut ecosystem: the current landscape and outlook of artificial microbiome therapeutics. | Lancet Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/38604200 | PubMed |
| 12 | 31,942,051 | The arms race between bacteria and their phage foes. | Nature | 2020 | https://conductscience.org/library/papers/31942051 | PubMed |
| 13 | 36,553,231 | Orthopedic Device-Related Infections Due to Emerging Pathogens Diagnosed by a Combination of Microbiological Approaches: Case Series and Literature Review. | Diagnostics (Basel) | 2022 | https://conductscience.org/library/papers/36553231 | PubMed |
| 14 | 37,031,199 | The evolution and international spread of extensively drug resistant Shigella sonnei. | Nat Commun | 2023 | https://conductscience.org/library/papers/37031199 | PubMed |
| 15 | 30,585,199 | Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System. | Viruses | 2018 | https://conductscience.org/library/papers/30585199 | PubMed |
| 16 | 37,336,428 | The current status of phage therapy and its advancement towards establishing standard antimicrobials for combating multi drug-resistant bacterial pathogens. | Microb Pathog | 2023 | https://conductscience.org/library/papers/37336428 | PubMed |
| 17 | 37,932,122 | Towards Standardization of Phage Susceptibility Testing: The Israeli Phage Therapy Center "Clinical Phage Microbiology"-A Pipeline Proposal. | Clin Infect Dis | 2023 | https://conductscience.org/library/papers/37932122 | PubMed |
| 18 | 40,298,495 | The Impact of Antibiotic Therapy on Intestinal Microbiota: Dysbiosis, Antibiotic Resistance, and Restoration Strategies. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/40298495 | PubMed |
| 19 | 35,625,199 | Bacteriophage Tail Proteins as a Tool for Bacterial Pathogen Recognition-A Literature Review. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35625199 | PubMed |
| 20 | 29,886,256 | High precision microfluidic microencapsulation of bacteriophages for enteric delivery. | Res Microbiol | 2018 | https://conductscience.org/library/papers/29886256 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,505,598 | Artificial Intelligence in Bacteriophage Science: A Comprehensive Narrative Review of Applications, Challenges, and Translational Opportunities. | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/42505598 | PubMed |
| 42,353,191 | Akkermansia muciniphila Alleviates Enterococcus faecalis-Exacerbated Alcoholic Liver Injury by Modulating Gut Microbiota and Barrier Function. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353191 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41892478
GET https://conductscience.org/api/papers/v1/41892478/references?page=2